In in-house step 3, we ulteriorly quantified MEF2C-AS1 methylation levels among 81 NAA, 81 AA, and 286 CRC patients by the MassARRAY method to elucidate its methylation status at all stages of colorectal carcinogenesis. The gene discussed is MEF2C; the disease is colorectal carcinoma.